Alkylated chitosan-attapulgite composite sponge for rapid hemostasis
Xue Chen1, Guoliang Yan2, Ming Chen3
1Department of Marine Biological Science & Technology, College of Ocean and Earth Sciences, Xiamen University, Xiamen 361102, China; State-Province Joint Engineering Laboratory of Marine Bioproducts and Technology, Xiamen University, Xiamen 361102, China.
Biomaterials Advances
|August 2, 2023
Summary
A novel composite sponge (ACATS) effectively stops bleeding rapidly. This advanced hemostatic material, made from alkylated chitosan and attapulgite, shows superior performance in preclinical models.
Area of Science:
- Biomaterials Science
- Hemostasis Research
- Polymer Chemistry
Background:
- Uncontrolled bleeding poses significant clinical challenges.
- Development of advanced hemostatic agents is crucial for emergency medicine.
- Chitosan-based materials show promise but require optimization for enhanced efficacy.
Purpose of the Study:
- To develop and characterize a novel composite sponge (ACATS) for rapid hemostasis.
- To optimize the composition of ACATS for superior hemostatic performance.
- To evaluate the in vivo hemostatic efficacy of ACATS compared to a commercial control.
Main Methods:
- Synthesis of alkylated chitosan (AC) and composite sponge (ACATS) with attapulgite (AT).
- Characterization of ACATS structure, including hierarchical porosity and biocompatibility.
- In vivo evaluation of hemostatic performance using a rabbit carotid artery injury model.
Main Results:
- Optimized ACATS (5.9% N-alkylation, 3:1 AC/AT ratio) exhibited a hierarchical porous structure and good biocompatibility.
- ACATS achieved rapid hemostasis in 235 ± 64 s with 8.4 ± 4.0 g blood loss.
- Significantly outperformed Celox (602 ± 101 s, 22.3 ± 2.4 g blood loss).
- ACATS rapidly interacted with blood components, promoting thrombus formation and coagulation.
Conclusions:
- ACATS is a highly effective composite sponge for rapid hemostasis.
- The optimized ACATS demonstrates superior performance compared to existing hemostatic agents.
- ACATS holds potential for clinical applications in managing severe bleeding.
